{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:51:25Z","timestamp":1790412685372,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.transci.2025.104115","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T20:59:04Z","timestamp":1743541144000},"page":"104115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Twenty years of the four-factor prothrombin complex concentrate Octaplex\/Balfaxar: A narrative review"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-5660","authenticated-orcid":false,"given":"Keyvan","family":"Karkouti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gareis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Brandst\u00e4tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pichotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti Mehta","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.transci.2025.104115_bib1","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/IJCIIS.IJCIIS_40_17","article-title":"Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding","volume":"8","author":"Holt","year":"2018","journal-title":"Int J Crit Illn Inj Sci"},{"key":"10.1016\/j.transci.2025.104115_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcrc.2016.02.018","article-title":"Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?","volume":"33","author":"Mangram","year":"2016","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-0042-1758653","article-title":"3-factor versus 4-factor prothrombin complex concentrates for the reversal of vitamin K antagonist-associated coagulopathy: a systematic review and meta-analysis","volume":"123","author":"Puchstein","year":"2023","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.transci.2025.104115_bib6","unstructured":"Baskaran J., Lopez R.A., Cassagnol M. Prothrombin complex concentrate. StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2022."},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.transci.2025.104115_bib8","unstructured":"Octapharma. Octaplex SmPC. \u3008https:\/\/www.medicines.org.uk\/emc\/product\/6566\/smpc#gref\u3009; 2022. [Accessed 01 May 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib9","unstructured":"Octapharma. BALFAXAR Prescribing Information. \u3008https:\/\/www.fda.gov\/media\/170477\/download\u3009; 2023. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib10","unstructured":"CSL Behring. BERIPLEX Summary of Product Characteristics. \u3008https:\/\/www.medicines.org.uk\/emc\/product\/6354\/smpc\u3009; 2021. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib11","unstructured":"CSL Behring. KCENTRA Prescribing Information. \u3008https:\/\/www.fda.gov\/media\/85512\/download\u3009; 2013. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib12","unstructured":"Sanquin. COFACT Summary of Product Characteristics. \u3008https:\/\/www.sanquin.org\/binaries\/content\/assets\/en\/products-services\/plasma-products\/product-charasteristics\/cofact-spc-uk.pdf\u3009; 2021. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib13","unstructured":"Haute Autorite De Sante. KANOKAD 25 IU\/mL (LFB-Biomedicants). \u3008https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2011-03\/kanokad_ct_6278.pdf\u3009; 2009. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib14","unstructured":"Takeda. Prothromplex SmPC. \u3008https:\/\/www.medicines.org.uk\/emc\/product\/15237\/smpc\u3009; 2023. [Accessed 21 June 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib15","unstructured":"Takeda. FEIBA Summary of Product Characteristics. \u3008https:\/\/www.medicines.org.uk\/emc\/product\/9192\/smpc\u3009; 2021. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib16","unstructured":"Takeda. FEIBA Prescribing Information. \u3008https:\/\/www.fda.gov\/media\/78852\/download?attachment\u3009; 1986. [Accessed 07 Feb 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib17","unstructured":"Grifols. PROFILNINE SD Package Insert. \u3008https:\/\/www.fda.gov\/media\/80956\/download?attachment\u3009; 2010. [Accessed 21 June 2024]."},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2007.02.009","article-title":"Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation","volume":"121","author":"Riess","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.transci.2025.104115_bib19","unstructured":"U. S. Food and Drug Administration. BALFAXAR Biologics License Application (BLA) approval. https:\/\/www.fda.gov\/media\/170486\/download?attachment; 2023. [Accessed 01 May 2024]."},{"key":"10.1016\/j.transci.2025.104115_bib20","unstructured":"Octapharma. Data on file. 2023."},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0049-3848(00)00339-X","article-title":"Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity","volume":"100","author":"Josi\u0107","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.transci.2025.104115_bib22","unstructured":"Octapharma. Octaplex Product Monograph. \u3008https:\/\/www.octapharma.ca\/api\/download\/x\/8468f1f57c\/octaplex-pm-en.pdf\u3009; 2017. [Accessed 01\/09]."},{"key":"10.1016\/j.transci.2025.104115_bib23","series-title":"Prothrombin Complex. Production of plasma proteins for therapeutic use","first-page":"65","author":"R\u00f6misch","year":"2013"},{"issue":"11","key":"10.1016\/j.transci.2025.104115_bib24","article-title":"Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding","volume":"11","author":"Hayes","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.transci.2025.104115_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.24758","article-title":"Vitamin K antagonist reversal for urgent surgery using 4-factor prothrombin complex concentrates: a randomized clinical trial","volume":"7","author":"Sarode","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.transci.2025.104115_bib26","first-page":"3","article-title":"Comparative user preference study demonstrating improved usability and design of a new transfer device for four-factor prothrombin complex concentrate","volume":"2024","author":"W\u00fchrer","year":"2024","journal-title":"18th World Congr Anaesthesiol (WCA2024)"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/rth2.12015","article-title":"The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro","volume":"1","author":"Schultz","year":"2017","journal-title":"Res Pr Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11239-019-01984-w","article-title":"Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol","volume":"50","author":"Fuh","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.transci.2025.104115_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.transci.2012.03.021","article-title":"Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol","volume":"46","author":"Wozniak","year":"2012","journal-title":"Transfus Apher Sci"},{"issue":"7","key":"10.1016\/j.transci.2025.104115_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1537-2995.2012.03924.x","article-title":"The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin","volume":"53","author":"Varga","year":"2013","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib32","article-title":"Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing","volume":"7","author":"Chiasakul","year":"2023","journal-title":"Res Pr Thromb Haemost"},{"key":"10.1016\/j.transci.2025.104115_bib33","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1182\/blood-2021-152697","article-title":"A Phase 3, randomized, double-blinded study of four-factor prothrombin complex concentrate in patients with acute major bleeding on direct oral anticoagulant therapy with factor Xa inhibitor: the LEX-210 study","volume":"138","author":"Sarode","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104115_bib34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2023-188990","article-title":"Updated protocol for the Phase 3, randomized, double-blinded LEX-210 study of four-factor prothrombin complex concentrate in patients with acute major bleeding on factor Xa inhibitor therapy","volume":"142","author":"Sarode","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.transci.2025.104115_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091381","article-title":"Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients requiring coagulation factor replacement: the LEX-211 (FARES-II) trial","volume":"14","author":"Karkouti","year":"2024","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.transci.2025.104115_bib36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology","volume":"167","author":"Mumford","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2018-06-820738","article-title":"Treatment of rare factor deficiencies other than hemophilia","volume":"133","author":"Menegatti","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2025.104115_bib38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/1076029617731596","article-title":"Congenital factor deficiencies in children: a report of a single-center experience","volume":"24","author":"\u015ealc\u0131o\u011flu","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4 1","key":"10.1016\/j.transci.2025.104115_bib39","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0049-3848(99)00077-8","article-title":"Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary","volume":"95","author":"Hellstern","year":"1999","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.transci.2025.104115_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.thromres.2004.04.004","article-title":"Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation","volume":"113","author":"Lubetsky","year":"2004","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib41","doi-asserted-by":"crossref","first-page":"P376","DOI":"10.1186\/cc5536","article-title":"Octaplex in routine clinical use for prophylaxis and therapy of bleeding in patients with prothrombin complex factor deficiency","volume":"11","author":"Franken","year":"2007","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/cc11923","article-title":"A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal","volume":"17","author":"Kerebel","year":"2013","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/cc11669","article-title":"Reversal of vitamin K antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of prothrombin complex concentrate (PCC) in current clinical practice","volume":"16","author":"Desmettre","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.transci.2025.104115_bib44","unstructured":"Goldstein J.N., Simonian G., Jr T.M., Hinterberger D., Gareis M., Sarode R. An investigational four-factor prothrombin complex concentrate for vitamin K antagonist reversal: hemostatic efficacy and safety demonstrated with and without concurrent vitamin K therapy. 43rd ISICEM International Symposium on Intensive Care & Emergency Medicine (ISICEM); 19-22 March 2024; Brussels Congress Center, Brussels 2024. https:\/\/doi.org\/10.2450\/2010.0149-09."},{"key":"10.1016\/j.transci.2025.104115_bib45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood-2022-168890","volume":"140","author":"Sarode","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12873-022-00568-x","article-title":"Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis","volume":"22","author":"Margraf","year":"2022","journal-title":"BMC Emerg Med"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.thromres.2011.07.024","article-title":"Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy","volume":"129","author":"Majeed","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.transci.2025.104115_bib48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/tme.12371","article-title":"Reversal of warfarin anticoagulation using prothrombin complex concentrate at 25 IU kg(-1): results of the RAPID study","volume":"27","author":"Appleby","year":"2017","journal-title":"Transfus Med"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1503\/cjs.018017","article-title":"Results of Octaplex for reversal of warfarin anticoagulation in patients with hip fracture","volume":"62","author":"Ng","year":"2019","journal-title":"Can J Surg"},{"key":"10.1016\/j.transci.2025.104115_bib51","doi-asserted-by":"crossref","first-page":"k2505","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1358863X221101926","article-title":"Oral anticoagulation therapies among Medicare beneficiaries: utilization and costs","volume":"27","author":"Parikh","year":"2022","journal-title":"Vasc Med"},{"issue":"6","key":"10.1016\/j.transci.2025.104115_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib54","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/asheducation-2016.1.612","article-title":"Reversal of direct oral anticoagulants: a practical approach","volume":"2016","author":"Shih","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1S 1","key":"10.1016\/j.transci.2025.104115_bib55","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MEG.0000000000002035","article-title":"Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter? - A systematic review and network meta-analysis","volume":"33","author":"Radadiya","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/medicines6040103","article-title":"Direct-acting oral anticoagulants and their reversal agents-an update","volume":"6","author":"Kustos","year":"2019","journal-title":"Medicines"},{"issue":"19","key":"10.1016\/j.transci.2025.104115_bib57","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.transci.2025.104115_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051003","volume":"11","author":"da Luz","year":"2021","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","article-title":"Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022","volume":"40","author":"Kietaibl","year":"2023","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"10.1016\/j.transci.2025.104115_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/anae.15181","article-title":"A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients","volume":"76","author":"Erdoes","year":"2021","journal-title":"Anaesthesia"},{"key":"10.1016\/j.transci.2025.104115_bib61","doi-asserted-by":"crossref","unstructured":"Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C., Meesters M.I., Milojevic M., Benedetto U., Bolliger D., et al. 2017 EACTS\/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32(1):88-120. https:\/\/doi.org\/https:\/\/doi.org\/10.1053\/j.jvca.2017.06.026.","DOI":"10.1053\/j.jvca.2017.06.026"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib64","first-page":"1","article-title":"New agents for DOAC reversal: a practical management review","volume":"29","author":"White","year":"2022","journal-title":"Br J Cardiol"},{"issue":"3","key":"10.1016\/j.transci.2025.104115_bib65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.annemergmed.2023.04.015","article-title":"Clinical relevance of preclinical and clinical studies of four-factor prothrombin complex concentrate for treatment of bleeding related to direct oral anticoagulants","volume":"82","author":"Sarode","year":"2023","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12245-018-0215-6","article-title":"The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review","volume":"11","author":"Hoffman","year":"2018","journal-title":"Int J Emerg Med"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1051\/ject\/202153097","article-title":"STS\/SCA\/AmSECT\/SABM update to the clinical practice guidelines on patient blood management","volume":"53","author":"Tibi","year":"2021","journal-title":"J Extra Corpor Technol"},{"issue":"15","key":"10.1016\/j.transci.2025.104115_bib68","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib69","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.transci.2025.104115_bib71","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jtha.2024.07.002","article-title":"Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors","volume":"22","author":"Schulman","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib72","article-title":"A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding","volume":"5","author":"Jaspers","year":"2021","journal-title":"Res Pr Thromb Haemost"},{"issue":"6","key":"10.1016\/j.transci.2025.104115_bib73","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/trf.12970","article-title":"A multicenter study of plasma use in the United States","volume":"55","author":"Triulzi","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1537-2995.2010.02798.x","article-title":"The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children","volume":"51","author":"Stanworth","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2025.104115_bib75","article-title":"Fresh frozen plasma for cardiovascular surgery","author":"Desborough","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib76","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1213\/ANE.0000000000001897","article-title":"Therapeutic plasma transfusion in bleeding patients: a systematic review","volume":"124","author":"Levy","year":"2017","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/ejcts\/ezx325","article-title":"2017 EACTS\/EACTA Guidelines on patient blood management for adult cardiac surgery","volume":"53","author":"Pagano","year":"2017","journal-title":"Eur J Cardio-Thorac Surg"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib78","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3936","article-title":"Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial","volume":"4","author":"Karkouti","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.transci.2025.104115_bib79","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/anae.15327","article-title":"Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial)","volume":"76","author":"Green","year":"2021","journal-title":"Anaesthesia"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib80","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.athoracsur.2018.10.013","article-title":"Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis","volume":"107","author":"Roman","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"16","key":"10.1016\/j.transci.2025.104115_bib81","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.2023.4080","article-title":"Efficacy and safety of early administration of 4-factor prothrombin complex concentrate in patients with trauma at risk of massive transfusion: the PROCOAG randomized clinical trial","volume":"329","author":"Bouzat","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib82","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/anae.12901","article-title":"Management of traumatic haemorrhage \u2013 the European perspective","volume":"70","author":"Schochl","year":"2015","journal-title":"Anaesthesia"},{"key":"10.1016\/j.transci.2025.104115_bib83","first-page":"160S","article-title":"Pharmacology and management of the vitamin K antagonists: American College of","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest Physicians Evid-Based Clin Pract Guidel (8th Ed) Chest"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/cc13982","article-title":"Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients","volume":"18","author":"Schochl","year":"2014","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.transci.2025.104115_bib85","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0037-1613258","article-title":"The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding","volume":"88","author":"Al Dieri","year":"2002","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.transci.2025.104115_bib86","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13054-023-04688-z","article-title":"Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses","volume":"27","author":"Hannadjas","year":"2023","journal-title":"Crit Care"},{"key":"10.1016\/j.transci.2025.104115_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bja.2024.10.047","article-title":"Altered thrombin generation with prothrombin complex concentrate is not detected by viscoelastic testing: an in vitro study","author":"Hofmann","year":"2025","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.transci.2025.104115_bib88","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/vox.12353","article-title":"Four-factor prothrombin complex concentrates in paediatric patients - a retrospective case series","volume":"110","author":"Noga","year":"2016","journal-title":"Vox Sang"},{"issue":"5","key":"10.1016\/j.transci.2025.104115_bib89","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/pan.13839","article-title":"The use of prothrombin complex concentrate as a warfarin reversal agent in pediatric patients undergoing orthotopic heart transplantation","volume":"30","author":"Sisti","year":"2020","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.transci.2025.104115_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221078842","article-title":"Andexanet alfa versus prothrombin complex concentrates\/blood products as apixaban\/rivaroxaban reversal agents: a survey among pediatric hematologists","volume":"28","author":"Rodriguez","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.transci.2025.104115_bib91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1055\/s-0039-1700953","article-title":"Single-center use of prothrombin complex concentrate in pediatric patients","volume":"9","author":"Karube","year":"2020","journal-title":"J Pedia Intensive Care"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:25:25Z","timestamp":1762547125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1473050225000497"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104115","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twenty years of the four-factor prothrombin complex concentrate Octaplex\/Balfaxar: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104115"}}